Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Study hints of rituximab MS benefit
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
HL-A antigens and multiple sclerosis.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Signal Transduction in the Blood-Brain Barriers
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Immunology 2013
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.

Pages